JEIL PHARMACEUTICAL secures South Korea rights for Shionogis antibiotic Petrozajoo JEIL PHARMACEUTICAL prepares to enhance ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

A clinical trial by Shionogi is a milestone in the search to treat Jordan's Syndrome, a rare genetic disorder named after a California lobbyist's daughter.

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its ...

The state’s insurance commissioner blocked a State Farm request to raise rates as wildfire insurance claims continue to roll in.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, is navigating a critical phase in its evolution.

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.